Characterization of the parietal intestinal microbiota in colon cancer
https://doi.org/10.18699/SSMJ20210210
Abstract
Introduction. Colon cancer (RCC) clinically manifests itself in the late stages, therefore, early diagnosis presents significant difficulties. There are many types of microorganisms in the human colon that form symbiosis with intestinal cells to maintain normal function. Аim of the study was to determine the composition of the parietal microflora of the colon under conditions of a tumor process and to assess the possibility of using these data in the diagnosis of colon cancer. Material and methods. The main group included 63 patients operated on for cancer (adenocarcinoma) of the left half of the colon (descending, sigmoid, rectosigmoid regions) with I T1-2N0M0, II T3-4aN0M0, III T1-2N1M0 stages of the tumor process. Among them are 32 men and 31 women aged 20 to 75 years (57.7 ± 3.8 years). In all patients, before hospitalization, the tumor was confirmed by colonoscopy followed by histological examination. The group of clinical comparison in the amount of 25 people consisted of patients with chronic hemorrhoids without exacerbation, who underwent colonoscopy. Material from the main group, biopsies of tumor tissue and visually unchanged colon mucosa, were taken intraoperatively during tumor removal. In patients of the clinical comparison group, the material was taken during the colonoscopy process. The composition of the intestinal microbiota was determined by a bacteriological method. Results and discussion. As a result of comparing the colon microbiota of cancer patients and the clinical comparison group, statistically significant differences in the quantitative composition of Lactobacillus spp., Bifidobacterium spp., Bacteroides spp., Clostridium spp., Enterococcus spp., Escherichia coli (typical), Escherichia coli (lactose-negative), Enterobacteriaceae, Staphylococcus spp. (CNS), Candida spp. It was established for the first time that Bifidobacterium spp., Enterococcus spp. and the age of the patient can be further used in the diagnosis of a malignant process. Conclusion. The created additive model can be used as an additional screening criterion in the early diagnosis of colon cancer.
About the Authors
S. V. VolkovRussian Federation
Stepan V. Volkov
672090, Chita, Gorkogo str., 39a
S. L. Lobanov
Russian Federation
Sergey L. Lobanov, doctor of medical sciences, professor
672090, Chita, Gorkogo str., 39a
References
1. Dai Z., Zhang J., Wu Q., Chen J., Liu J., Wang L., Chen C., Xu J., Zhang H., Shi C., Li Z., Fang H., Lin C., Tang D., Wang D. The role of microbiota in the development of colorectal cancer. Int. J. Cancer. 2019; 145 (8): 2032–2041. doi: 10.1002/ijc.32017
2. Hernández-Luna M.A., López-Briones S., Luria-Pérez R. The four horsemen in colon cancer. J. Oncol. 2019; 2019: 5636272. doi: 10.1155/2019/5636272
3. Bahmani S., Azarpira N., Moazamian E. Anticolon cancer activity of Bifidobacterium metabolites on colon cancer cell line SW742. Turk. J. Gastroenterol. 2019; 30 (9): 835–842. doi: 10.5152/tjg.2019.18451
4. Sivan A., Corrales L., Hubert N., Williams J.B., Aquino-Michaels K., Earley Z.M., Benyamin F.W., Lei Y.M., Jabri B., Alegre M.L., Chang E.B., Gajewski T.F. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015; 350 (6264): 1084–1089. doi: 10.1126/science.aac4255
5. Wei Y., Li F., Li L., Huang L., Li Q. Genetic and biochemical characterization of an exopolysaccharide with in vitro antitumoral activity produced by Lactobacillus fermentum YL-11. Front. Microbiol. 2019; 10: 2898. doi: 10.3389/fmicb.2019.02898
6. Dai Z., Zhang J., Wu Q., Chen J., Liu J., Wang L., Chen C., Xu J., Zhang H., Shi C., Li Z., Fang H., Lin C., Tang D., Wang D. The role of microbiota in the development of colorectal cancer. Int. J. Cancer. 2019; 145 (8): 2032–2041. doi: 10.1002/ijc.32017
7. Zamani S., Taslimi R., Sarabi A., Jasemi S., Sechi L.A., Feizabadi M.M. Enterotoxigenic Bacteroides fragilis: a possible etiological candidate for bacterially-induced colorectal precancerous and cancerous lesions. Front. Cell Infect. Microbiol. 2020; 9: 449. doi: 10.3389/fcimb.2019.00449
8. Sheng Q.S., He K.X., Li J.J., Zhong Z.F., Wang F.X., Pan L.L., Lin J.J. Comparison of gut microbiome in human colorectal cancer in paired tumor and adjacent normal tissues. Onco Targets Ther. 2020; 13: 635–646. doi: 10.2147/OTT.S218004
9. Zorron Cheng Tao Pu L., Yamamoto K., Honda T., Nakamura M., Yamamura T., Hattori S., Burt A.D., Singh R., Hirooka Y., Fujishiro M. Microbiota profile is different for early and invasive colorectal cancer and is consistent throughout the colon. J. Gastroenterol. Hepatol. 2019; 35 (3): 433–437. doi: 10.1111/jgh.14868